Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: PBTZ169 1280 mg MD
Drug: PBTZ169 960 mg SD
Drug: PBTZ169 640 mg OD
Drug: PBTZ169 640 mg BiD
Drug: PBTZ169 1280 mg SD

Registration Number: NCT04150224

Lead Sponsor: Nearmedic Plus LLC

Brief Summary: Open-label prospective non-comparative ascending dose randomized cohort study of single and multiple oral administration of PBTZ169 (capsules 80 mg) in healthy volunteers

Detailed Description: Open-label prospective non-comparativerandomized cohort study of safety, tolerability, pharmacokinetics and the effect of food of PBTZ169 in adult healthy volunteers after single and multiple oral administration. Study was conducted in one study center in the Russian Federation. The study included two stages:

Stage 1 - single or double oral administration with dose escalation (fasted/after meal) in 5 cohorts 10 healthy volunteers each plus 5 back-up volunteers;

Stage 2 - multiple oral administration once a day after meal for 14 days in 1 cohort of 10 healthy volunteers.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 60

Inclusion Criteria

Written informed consent from the volunteer.
Men and women aged 18-45 years, inclusive.
Body mass index of 18.5-30 kg/m2.
Verified "healthy" diagnosis based on physical examination, vital signs, standard laboratory tests (complete blood count and biochemical blood test, urine analysis) and instrumental tests (ECG, fluorography examination or X-ray examination).
Negative results of tests for human immunodeficiency virus (HIV), syphilis, hepatitis B (Hbs Ag) and hepatitis C (antibodies to HCV).
Ability to comply with all the requirements of the protocol in the opinion of the investigator.
Consent of the participant and his/her partner to use reliable contraceptive methods during the study and within 90 days after the end of their participation. A reliable method of contraception is a combination of a male condom with at least one of the following methods:
- hormonal contraceptives used by the male's partner (only if she does not participate in this clinical study);
- use of aerosols, creams, suppositories and other agents containing spermicides;
- use of intrauterine device by female partner.

Exclusion Criteria

History of allergies, including at least one episode of allergy to medications.
Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, ENT, as well as diseases of the gastrointestinal tract, liver, kidneys, blood, skin.
Hypolactasia (lactose intolerance, lactase deficiency) or glucose-galatose malabsorption in medical history.
Chronic eye diseases except for myopia, hypermetropia and astigmatism of mild and moderate severity.
Surgeries on the gastrointestinal tract (except for appendectomy done more than 1 year before screening).
Regular administration or use (including externally) of hormonal agent for more than 1 week less than 45 days before screening
Regular administration of medicinal products less than 4 weeks before screening.
Use of medicinal products that have a pronounced effect on liver function or hemodynamics (barbiturates, omeprazole, cimetidine, etc.) less than 30 days before screening.
Positive test for narcotics and psychotropic products.
Blood pressure after resting in supine position for at least 5 minutes above 130 mm Hg (systolic blood pressure) and 90 mm Hg (diastolic blood pressure) or below 110 mm Hg (systolic blood pressure) and 60 mm Hg (diastolic blood pressure).
Heart rate (according to ECG) after resting in supine position for at least 5 minutes above 90 bpm or below 60 bpm.
Blood donation (450 mL of blood or plasma and more) less than 3 months before the screening.
Acute infectious diseases less than 4 weeks before screening.
Administration of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to 500 mL of beer, 200 mL of wine or 50 mL of a spirit) or history of alcoholism, drug abuse, substance abuse.
Mental diseases.
Smoking for three months before screening.
Participation in any clinical study less than 3 months before screening.
Planned conception or sperm donation during the study after the administration of the investigational product or within 3 months after the last administration of the product.
Positive pregnancy test for women.
Breastfeeding period.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 5 (C5), PBTZ169	PBTZ169 1280 mg MD	Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days
Cohort 2 (C2), PBTZ169	PBTZ169 960 mg SD	Single dose of PBTZ169: 960 mg fasted
Cohort 1 (C1A), PBTZ169	PBTZ169 640 mg OD	Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.
Cohort 1 (C1B), PBTZ169	PBTZ169 640 mg OD	Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.
Cohort 3 (C3), PBTZ169	PBTZ169 640 mg BiD	Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg
Cohort 4 (C4), PBTZ169	PBTZ169 1280 mg SD	Single dose of PBTZ169: 1280 mg fasted

Primary Outcome Measures

Name	Time	Method
Number of Adverse Events	Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake	Safety and tolerability: number of (S)AEs
Number of Subjects With AEs	Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake	Safety and tolerability: number of subjects with adverse events

Secondary Outcome Measures

Name	Time	Method
Results of Physical Examination: CS Deviations	Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake	Safety and tolerability: number of physical examinations with CS deviations in results
Peak Plasma Concentration (Сmax)	In the dosing interval (up to 72 hours after the last drug administration)	Сmax of PBTZ169 at the timepoints: C1A, C1B, C2 and C4: point 0 (-5 min to -1 min), 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 9:00, 12:00, 24:00, 48:00 and 72:00 (h:min). C3 (two administrations): point 0 (-5 min to -1 min), 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 9:00, 12:00 (the point before the second administration from -5 min to -1 min), 12:30, 13:00, 13:30, 14:00, 15:00, 16:00, 18:00, 21:00, 24:00, 48:00 , 72:00 (h:min) after the first administration of the medicinal product. C5 (14 days of intake): 5 minutes before the administration (only until the first dose), 0 min and within 24 h after the administration of the 1st, 7th and last (14th) dose: 0:15, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 (h:min after the administration of a dose of the medicinal product); at 48 h and 72 h points after the last (14th) dose of PBTZ169
Trough Concentration With Repeated Administration (Ctrough)	Up to 72 hours after the last drug administration	PBTZ169 concentration before drug intake (Days 2 - 15)
CS Changes in Vital Signs	Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake	Safety and tolerability:Clinically significant changes in vital signs (blood pressure, HR, body temperature, RR)
Plasma Half-life Time (T1/2)	Up to 72 hours after the last drug administration
ECG Results (Safety and Tolerability)	Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake	Clinically significant abnormal deviations in ECG findings
Laboratory Examinations Results (Safety and Tolerability)	Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake	Complete blood count, biochemical blood test, urine analysis
Time to Reach Maximum Concentration (Tmax)	Up to 72 hours after the last drug administration	Cohort 3: Tmax relative to the time of administration in any dosage interval
Area Under the Concentration-time Curve (AUC0 t)	Up to 72 hours after the last drug administration	In the time interval from 0 to time (t) when the last blood sample is collected with a concentration above the limit of quantification. C5: for the data of Day 14 based on measurements within 72 hours after the last dose administration
Area Under the Concentration-time Curve (AUC0-∞)	Up to 72 hours after the last drug administration	In the time interval from 0 to infinity
Area Under the Concentration-time Curve (AUC0-24)	In the dosing interval (up to 24 hours after drug administration)	C5 (multiple administration once a day for 14 days): AUC0-24 was calculated based on measurements within 24 hours after PBTZ169 intake
Total Clearance (Clt/F)	Up to 72 hours after the last drug administration
Volume of Distribution (Vd/F)	Up to 72 hours after the last drug administration
Elimination Constant Kel	Up to 72 hours after the last drug administration
Relative Bioavailability	Up to 72 hours after the last drug administration	f=AUC0-∞(T)/AUC0-∞(R); f'=AUC0-t(T)/AUC0-t(R) Test (T) - PBTZ169 640 mg after meals, reference (R) - PBTZ169 640 mg fasted
Relative Degree of Absorption	Up to 72 hours after the last drug administration	f"=Cmax(T)/Cmax(R). Test (T) - PBTZ169 640 mg after meals, reference (R) - PBTZ169 640 mg fasted
Number of Subjects With CS Changes in Vital Signs	Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake	Safety and tolerability: No. of sbjs with clinically significant changes in vital signs (blood pressure, HR, body temperature, RR)

Trial Locations

Locations (1): Clinical hospital at the Yaroslavl station of the Open Joint Stock Company Russian Railways
🇷🇺
Yaroslavl, Russian Federation
Clinical hospital at the Yaroslavl station of the Open Joint Stock Company Russian Railways
🇷🇺Yaroslavl, Russian Federation